{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:46:34Z","timestamp":1792025194141,"version":"4.4.0"},"reference-count":30,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T00:00:00Z","timestamp":1662249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>There are few studies describing aminoglycoside pharmacokinetics during continuous renal replacement therapy (CRRT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>\n                      To characterize the effect of CRRT on aminoglycoside clearance and volume of distribution (\n                      <jats:italic toggle=\"yes\">\n                        V\n                        <jats:sub>d<\/jats:sub>\n                      <\/jats:italic>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Retrospective observational pharmacokinetic study of adult critically ill oncologic patients who received a first dose of amikacin or tobramycin during CRRT between February 2012 and May 2017. Study outcomes included aminoglycoside clearance,\n                      <jats:italic toggle=\"yes\">\n                        V\n                        <jats:sub>d<\/jats:sub>\n                      <\/jats:italic>\n                      , and attainment of the target peak: MIC (minimum inhibitory concentration) ratio as a surrogate for dosing appropriateness.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In total, 80 patients were included, sustained low-efficiency dialysis (SLED), n = 49; continuous venovenous hemodialysis (CVVHD), n = 19; continuous venovenous hemofiltration (CVVH), n = 12. Fifty-one patients received amikacin at a median dose of 14.5 mg\/kg per actual body weight and achieved a median peak level of 26.7 mg\/L. Twenty-nine patients received tobramycin at a median dose of 6.5 mg\/kg actual body weight and achieved a median peak level of 10.3 mg\/L. The median aminoglycoside clearance was 63.1 mL\/min and was similar between CRRT modality groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.97). The median\n                      <jats:italic toggle=\"yes\">\n                        V\n                        <jats:sub>d<\/jats:sub>\n                      <\/jats:italic>\n                      was 0.47 L\/kg and was different between the SLED and CVVH groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.007). Attainment of target peak: MIC occurred in 29% in the total study population and 44% in the subgroup of 23 patients with isolates tested for aminoglycoside susceptibility.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Relevance:<\/jats:title>\n                    <jats:p>\n                      Critically ill oncology patients undergoing CRRT exhibited reduced clearance and expanded\n                      <jats:italic toggle=\"yes\">\n                        V\n                        <jats:sub>d<\/jats:sub>\n                      <\/jats:italic>\n                      that was not significantly different between CRRT modalities. Current dosing regimens led to low peak concentrations and poor attainment of pharmacokinetic targets.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280221120600","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T01:45:06Z","timestamp":1662342306000},"page":"629-636","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Aminoglycoside Pharmacokinetics in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy"],"prefix":"10.1177","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2378-1981","authenticated-orcid":false,"given":"Chelsea K.","family":"Krueger","sequence":"first","affiliation":[{"name":"Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Bruno","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank P.","family":"Tverdek","sequence":"additional","affiliation":[{"name":"Seattle Cancer Care Alliance, University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ala","family":"Abudayyeh","sequence":"additional","affiliation":[{"name":"Section of Nephrology, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,9,4]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000217961.75225.E9"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181e96b91."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/ccm.0b013e3181eb3ccd."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00115-10."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/155.1.93."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.5.562."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199006000-00023."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199104000-00029."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00374-11."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00828-16."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.01.026"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/2050-6511-13-14."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.ndt.a027617"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-013-0012-8."},{"issue":"6","key":"e_1_3_2_16_2","first-page":"742","article-title":"Pharmacokinetics and clearance of ciprofloxacin and amikacin in continuous hemodialysis","volume":"123","author":"Cotera A","year":"1995","unstructured":"Cotera A, Aguila R, Gaete L, Saffie A, Lorca E, Thambo S. Pharmacokinetics and clearance of ciprofloxacin and amikacin in continuous hemodialysis. Rev Med Chil. 1995;123(6):742-748.","journal-title":"Rev Med Chil"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.3.464"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00222-10."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00819.x"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01758-10."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00441-10"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.09.006."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.3.650"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1977213362."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.5.1115"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc5713"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809402800719"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.23.6.888"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.3.4.469"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2014.07.006."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/0885066618754784."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221120600","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280221120600","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221120600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:17:05Z","timestamp":1777375025000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280221120600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,4]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1177\/10600280221120600"],"URL":"https:\/\/doi.org\/10.1177\/10600280221120600","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,4]]}}}